ReviewTopics in antiviral medicine
Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.
Review in Topics in antiviral medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.Hepatology (Baltimore, Md.) · 2015Trial
- Article
- Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols.Virology journal · 2020Article
- The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.Journal of clinical and translational hepatology · 2017Review
- Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.Clinical pharmacokinetics · 2016Review
- Article
- Review
- Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.Open forum infectious diseases · 2015Article
- New treatments for chronic hepatitis C: an overview for paediatricians.World journal of gastroenterology · 2014Review
- Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.World journal of gastroenterology · 2014Review
- The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.Antimicrobial agents and chemotherapy · 2014Article
- Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Antimicrobial agents and chemotherapy · 2014Article
- Article
- The flavivirus protease as a target for drug discovery.Virologica Sinica · 2013Review
- Management of hepatitis C virus infection: the basics.Topics in antiviral medicine · 2012Review
- What role (if any) does the highly conserved CSB-PGBD3 fusion protein play in Cockayne syndrome?Mechanisms of ageing and developmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The addition of the hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir to peginterferon alfa with ribavirin therapy has increased cure rates in HCV infection. Numerous other direct-acting antivirals (DAAs) are in advanced stages of development, including next-generation protease inhibitors, nonstructural protein (NS) 5A inhibitors, and nonnucleoside and nucleos(t)ide NS5B polymerase inhibitors. The classes have different potencies, different resistance mutation profiles, and different barriers to the emergence of resistance. A comprehensive table of resistance mutations for classes of DAAs is presented. Numerous combinations of DAAs with or without ribavirin have been evaluated in early studies of interferon alfa-free regimens, with results indicating that cure is indeed possible with such therapy and suggesting that identification of regimens that could produce cure in the majority of patients may occur within the foreseeable future. This article summarizes a presentation by David L. Wyles, MD, at the IAS-USA live continuing medical education activity held in New York in June 2012.
Indexed as
Identifiers
23154254PMC6148907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.